复合因子VIIa在人类受试者的组织因子抑制期间产生血栓的能力
P W Friederich1, M Levi, K A Bauer
1Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Netherlands.
Circulation
|May 31, 2001
概括
再组合因子VIIa (rVIIa) 可以逆转线虫抗凝蛋白c2的抗凝作用,这是一个组织因子抑制剂. 这一发现表明rVIIa可以作为与组织因子通路抑制剂相关的出血并发症的有效解药.
科学领域:
- 血液静止和血栓形成
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 组织因子-因子VIIa通路对于启动血液凝结至关重要.
- 针对这种途径的新型抗凝剂需要有效的逆转出血事件的策略.
- 复合性线虫抗凝蛋白c2 (rNAPc2) 是组织因子-因子VIIa复合物的特定抑制剂.
研究的目的:
- 调查复合因子VIIa (rVIIa) 在体内诱导血栓生成的潜力.
- 评估rVIIa在健康人群中逆转rNAPc2抗凝剂作用的疗效.
主要方法:
- 双盲随机交叉研究的设计.
- 在健康志愿者中给予rNAPc2,随后给予rVIIa.
- 监测前热血素时间,前热血素激活片段F1+2,以及血素-抗血素复合体.
主要成果:
- rNAPc2的使用延长了前热血素时间.
- 随后的rVIIa注射迅速纠正了前热血素时间,并诱导了显著的血栓生成.
- 在rVIIa给药后观察到F1+2和氨酸-抗氨酸复合物的水平增加.
- 激活X因子和IX激活的显著增加.
结论:
- 再组合因子VIIa即使在用组织因子-因子VIIa复合抑制剂治疗期间也有效诱导血栓生成.
- rVIIa显示出作为一种可行的抗毒剂的潜力,可以逆转组织因子通路抑制剂的作用.
- 这项研究强调了一种有前途的治疗策略,用于管理与新型抗凝药疗法相关的出血并发症.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.